Nijmegen, Netherlands
Nijmegen, Netherlands

Time filter

Source Type

Patent
Synthon Biopharmaceuticals B.V. and Yale University | Date: 2016-07-21

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours expressing HER2, wherein the human solid tumour expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2 or 1+ and HER2 FISH negative tumour tissue status.


Patent
Synthon Biopharmaceuticals B.V. and Yale University | Date: 2015-09-18

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours expressing HER2, wherein the human solid tumour expressing HER2 is endometrial cancer, in particular uterine serous carcinoma (USC). In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of endometrial cancer, notably USC, with HER2 IHC 2 or 1+ and HER2 FISH negative tumour tissue status.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2015-01-09

The present invention relates to a method for purifying a mixture of cysteine-linked antibody-drug conjugates, wherein the amount of non-conjugated antibody is in the range of 0-40% by weight, using hydrophobic interaction chromatography (HIC). The mixture is loaded onto a preparative HIC column using a 0.2-1.5 M aqueous salt solution, in which non-conjugated antibody is collected in a flow-through fraction, followed by elution of a purified mixture of cysteine-linked antibody-drug conjugates using a 0-100 mM aqueous salt solution.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2012-06-13

Compositions and methods are described for making and using transgenic plants and plant parts having at least one auxotrophic requirement for an essential compound such as an amino acid, carbohydrate, fatty acid, nucleic acid, vitamin, plant hormone, or precursor thereof. Transgenic plants and plants parts having at least one auxotrophic requirement can be effectively biocontained by withdrawal of the essential compound.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2012-12-14

A monoclonal secretory IgA antibody, which binds to and neutralizes human TNF. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2016-07-21

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).


Patent
Synthon Biopharmaceuticals B.V. | Date: 2016-09-21

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).


Patent
Synthon Biopharmaceuticals B.V. | Date: 2012-12-14

A monoclonal secretory IgA antibody, which binds to and neutralizes human p40 (the p40 subunit of IL-12 and IL-23). The secretory antibody is useful in treating a variety of inflammatory conditions in humans.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2012-12-14

Secretory IgA antibodies can be made by expression in a stably-transformed duckweed.


Patent
Synthon Biopharmaceuticals B.V. | Date: 2015-09-18

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumours and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumours with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

Loading Synthon Biopharmaceuticals BV collaborators
Loading Synthon Biopharmaceuticals BV collaborators